JP Morgan Private Wealth Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-275,000	Closed	-$1.29M	–	1746
2020 Q3	$1.29M	Hold	275,000	–	–	0.01%	785
2020 Q2	$1.68M	Buy	275,000 +231,839	+537%	+$955K	0.01%	634
2020 Q1	$98K	Buy	+43,161	New	+$183K	﹤0.01%	1365
2016 Q3	–	Sell	-9,523	Closed	-$394K	–	1290
2016 Q2	$394K	Buy	+9,523	New	+$414K	﹤0.01%	869

Other funds holding FPRX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Private Wealth Advisors's FPRX Position: Q4 2020 in Review

JP Morgan Private Wealth Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2020, closing a stake of 275,000 shares — an estimated $1.29M sold.

JP Morgan Private Wealth Advisors first reported a position in FPRX in Q2 2016 and held it in 4 quarters. The position peaked at $1.68M in Q2 2020. 125 funds tracked by Wall St. Rank hold FPRX as of Q4 2020.

JP Morgan Private Wealth Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
JP Morgan Private Wealth Advisors sold 275,000 Five Prime Therapeutics, Inc. shares in Q4 2020, an estimated $1.29M.
JP Morgan Private Wealth Advisors first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 4 quarters.
JP Morgan Private Wealth Advisors's Five Prime Therapeutics, Inc. position peaked at $1.68M in Q2 2020.
125 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2020.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.